Clinical Trial

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The study is an open-label, single arm, multicenter phase II trial investigating the clinical activity of a perioperative therapy consisting of a combination of pembrolizumab, trastuzumab and FLOT, followed by pembrolizumab plus trastuzumab alone for a maximum systemic treatment duration of one year in patients with Her-2 positive localized esophagogastric adenocarcinoma.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-11
notable Primary completion moved earlier: 2027-10 -> 2026-07-15 2026-08-11
minor Completion moved earlier: 2027-12 -> 2026-08-05 2026-08-11
Trial Details
NCT Number NCT05504720
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Merck Sharp & Dohme LLC, Organon Healthcare GmbH
Conditions Esophagogastric Adenocarcinoma
Enrollment 31 participants
Start Date 2023-02-13
Primary Completion 2026-07-15 (estimated)
Study Completion 2026-08-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-10